Literature DB >> 15372266

Myasthenic crisis after the cessation of FK506 in a patient with myasthenia gravis.

Tetsuro Konishi, Mitsuru Sanada, Kazuya Takehana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15372266     DOI： 10.1007/s00415-004-0504-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

1.  Clinical study of FK506 in patients with myasthenia gravis.

Authors:  Tetsuro Konishi; Yasumasa Yoshiyama; Masaharu Takamori; Koichi Yagi; Eiichiro Mukai; Takahiko Saida
Journal:  Muscle Nerve       Date:  2003-11       Impact factor: 3.217

2.  Successful treatment of myasthenia gravis with tacrolimus.

Authors:  Amelia Evoli; Chiara Di Schino; Francesca Marsili; Chiara Punzi
Journal:  Muscle Nerve       Date:  2002-01       Impact factor: 3.217

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  Myasthenia gravis: discontinuation of long-term azathioprine.

Authors:  M Michels; R Hohlfeld; H P Hartung; K Heininger; U A Besinger; K V Toyka
Journal:  Ann Neurol       Date:  1988-12       Impact factor: 10.422

Review 5.  Myasthenia gravis.

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

6.  Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus.

Authors:  Tetsushi Toyonaga; Tatsuya Kondo; Nobuhiro Miyamura; Taiji Sekigami; Kazuhiro Sonoda; Shoko Kodama; Atsuhisa Shirakami; Tetsuya Shirotani; Eiichi Araki
Journal:  Diabetes Res Clin Pract       Date:  2002-04       Impact factor: 5.602

Review 7.  Mode of action of tacrolimus (FK506): molecular and cellular mechanisms.

Authors:  A W Thomson; C A Bonham; A Zeevi
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

8.  Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.

Authors:  R Hohlfeld; K V Toyka; U A Besinger; B Gerhold; K Heininger
Journal:  Ann Neurol       Date:  1985-03       Impact factor: 10.422

9.  Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.

Authors:  Kimiaki Utsugisawa; Yuriko Nagane; Hisashi Yonezawa; Daiji Obara; Ryushi Kondoh; Hideo Tohgi
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

10.  Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell.

Authors:  K Tamura; T Fujimura; T Tsutsumi; K Nakamura; T Ogawa; C Atumaru; Y Hirano; K Ohara; K Ohtsuka; K Shimomura
Journal:  Transplantation       Date:  1995-06-15       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.